|
Abbott teams up with GlaxoSmithKline on cancer efforts |
|
Monday, 13 July 2009 10:37
|
| Abbott Laboratories (ABT) said Monday that it has entered into an agreement with GlaxoSmithKline Plc (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction technology, intended to screen non-small cell lung cancer tumors for expression of the MAGE-A3 antigen.
Are you watching the right charts? Here are 15 charts traders should see every day. 
-
Essential Reading for Traders
-
| | |
| | | | | GlaxoSmithKline's MAGE-A3 Antigen Specific Cancer Immunotherapy or ASCI candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the Phase III clinical study MAGRIT. To be eligible to receive GlaxoSmithKline's MAGE A3 ASCI, patients must have MAGE-A3 expressing NSCLC tumors. MAGE-A3 is a tumor-specific antigen that is expressed in non-small cell lung cancer and a wide variety of other cancers, but not in normal cells. Under terms of the agreement, Abbott, in conjunction with GlaxoSmithKline, will develop and commercialize a PCR test designed to detect MAGE A3 for use on the Abbott m2000 automated instrument system. Currently, there are no nucleic acid based tests approved by the U.S. Food and Drug Administration for use in identifying patients who may derive treatment benefits from targeted non-small cell lung cancer therapies.
More...
Free trading ideas and analysis are always found at LearningMarkets.com.
Keep up with us:
| |
|
